IL2 and pancreatic neoplasm: To compare the differentiation level in tumors by primary NK cells and sNK cells, we treated CSCs, oral squamous carcinoma stem-like cells (OSCSCs) (Fig. 4A) and pancreatic tumors MIA PaCA-2 (MP2) (Fig. 4B), with the supernatants derived from primary NK cells activated with IL-2 and anti-CD16 monoclonal antibodies (IL-2 + anti-CD16 mAbs), as primary NK cells treated with IL-2 + anti-CD16 mAbs has demonstrated higher levels of cytokine secretion compared to untreated or IL-2-treated primary NK cells [57], as well as from sNK cells.